BioMarin Pharmaceuticals (BMRN)

• Market cap: $11.7B
• 1 day: 0.46%
• 5 days: -8.95%
• 1 month: -8.42%
• 3 months: -11.43%
• 6 months: -27.32%
• Year to date: -7.46%
• 1 year: -34.14%
• 5 years: -30.29%
• 10 years: -37.95%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

36% more call options, than puts

Call options by funds: $152M | Put options by funds: $112M

1% more first-time investments, than exits

New positions opened: 87 | Existing positions closed: 86

1% more repeat investments, than reductions

Existing positions increased: 193 | Existing positions reduced: 191

1% less funds holding

Funds holding: 548 [Q2] → 542 (-6) [Q3]

4.99% less ownership

Funds ownership: 99.4% [Q2] → 94.41% (-4.99%) [Q3]

19% less capital invested

Capital invested by funds: $15.5B [Q2] → $12.6B (-$2.91B) [Q3]

33% less funds holding in top 10

Funds holding in top 10: 6 [Q2] → 4 (-2) [Q3]

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $65 6% upside
• Avg. target: $91 47% upside
• High target: $109 77% upside

9 analyst ratings

• positive: 5 56%
• neutral: 4 44%
• negative: 0 0%

Cantor Fitzgerald Olivia Brayer 27% 1-year accuracy 6 / 22 met price target	46% upside $90	Overweight Reiterated	12 Dec 2024
Wolfe Research Akash Tewari 8% 1-year accuracy 1 / 13 met price target	54% upside $95	Outperform Initiated	15 Nov 2024
Citigroup David Lebovitz 65% 1-year accuracy 11 / 17 met price target	32% upside $81	Neutral Maintained	30 Oct 2024
Canaccord Genuity Whitney Ijem 18% 1-year accuracy 7 / 40 met price target	37% upside $84	Hold Maintained	30 Oct 2024
JP Morgan Jessica Fye 47% 1-year accuracy 18 / 38 met price target	77% upside $109	Overweight Maintained	30 Oct 2024